POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
POINT
Biopharma Global Inc, engaged in the discovery, development, and global access
to life-changing radiopharmaceuticals, and Athebio AG (“Athebio”), credited
with the discovery and design of designed ankyrin repeat proteins (DARPins), announced
a collaboration and license agreement to develop and commercialize
DARPin-targeted radioligands (“Radio-DARPins”).
The
collaboration gives POINT exclusive access to Athebio’s intellectual property
and capabilities in DARPin development in the radioligand therapy field.
Together, the parties will collaborate in discovery, candidate selection and
preclinical development of Athebody® DARPins for use as Radio-DARPin drug
entities. POINT will be solely responsible for the clinical development and commercialization
of Radio-DARPins translated from the discovery collaboration.
To read more please visit:
Source: POINT